TVGN

Tevogen Bio Holdings Inc

Sep 17 • 04:00PM ET

0.8400

-0.0100 -1.18 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA CRSP GILD FATE EDIT ALLO IMTX ADAP PSTX BLUE

| Held by: VTI IWM IBB VTWO IWO IWN VXF IWC VTWG RSSL

Index	RUT	P/E	-	EPS (ttm)	-0.18	Insider Own	73.20%	Shs Outstand	193.69M	Perf Week	-3.72%
Market Cap	165.23M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	-0.99%	Shs Float	52.73M	Perf Month	-12.84%
Enterprise Value	180.90M	PEG	-	EPS next Q	-0.06	Inst Own	2.46%	Short Float	5.67%	Perf Quarter	-31.15%
Income	-31.30M	P/S	-	EPS this Y	-340.80%	Inst Trans	24.19%	Short Ratio	3.56	Perf Half Y	-26.96%
Sales	0.00M	P/B	-	EPS next Y	-8.03%	ROA	-818.81%	Short Interest	2.99M	Perf YTD	-18.45%
Book/sh	-0.09	P/C	239.47	EPS next 5Y	-	ROE	-124.74%	52W High	3.09 -72.82%	Perf Year	75.37%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	-388.63% -	ROIC	-	52W Low	0.26 228.64%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.94% 5.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-406.67%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.63	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.25	EPS Q/Q	22.34%	SMA20	-5.50%	Beta	-0.78	Target Price	10.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-15.45%	Rel Volume	0.43	Prev Close	0.85
Employees	18	LT Debt/Eq	-	Earnings	Aug 14	SMA200	-26.91%	Avg Volume	841.08K	Price	0.84
IPO	Jan 05, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	38.80% -	Trades		Volume	358,334	Change	-1.18%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-25	Initiated	D. Boral Capital	Buy	$10

Sep-10-25 11:59AM	Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston (GlobeNewswire)
Sep-09-25 03:15PM	Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection (GlobeNewswire)
Sep-08-25 09:27AM	Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform (GlobeNewswire)
Sep-04-25 03:48PM	Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas (GlobeNewswire)
Sep-03-25 04:15PM	Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2 (GlobeNewswire)
03:20PM	Loading…
Aug-27-25 03:20PM	Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure (GlobeNewswire)
Aug-26-25 02:50PM	Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity (GlobeNewswire)
Aug-25-25 03:10PM	Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions (GlobeNewswire)
Aug-22-25 03:25PM	Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma (GlobeNewswire)
Aug-19-25 03:40PM	REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts (GlobeNewswire)
12:10PM	Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum (GlobeNewswire)
Aug-18-25 05:50PM	Tevogen CEO Donates Personal Shares to Support Local Law Enforcement (GlobeNewswire)
05:15PM	Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery (GlobeNewswire)
Aug-14-25 03:55PM	Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected (GlobeNewswire)
Aug-13-25 03:53PM	Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
11:09AM	Loading…
Aug-12-25 11:09AM	Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction (PR Newswire)
Aug-11-25 03:45PM	Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion (GlobeNewswire) +8.83%
01:24PM	REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion (GlobeNewswire)
11:58AM	Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire)
09:28AM	REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
Aug-08-25 11:37AM	REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-07-25 09:00AM	Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy (GlobeNewswire) -8.75%
Aug-06-25 03:59PM	Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions (GlobeNewswire)
Aug-05-25 02:32PM	Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology (GlobeNewswire)
Aug-01-25 03:57PM	Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders (GlobeNewswire)
03:30PM	Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion (GlobeNewswire)
Jul-30-25 12:41PM	Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision (GlobeNewswire)
Jul-28-25 11:52AM	Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare (GlobeNewswire)
Jul-18-25 12:36PM	Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides (GlobeNewswire)
Jul-17-25 09:15AM	Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility (GlobeNewswire)
06:35PM	Loading…
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire)
11:57AM	Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch (GlobeNewswire)
Jul-14-25 09:30AM	Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs (GlobeNewswire) +5.88%
Jul-10-25 03:13PM	Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation (GlobeNewswire)
Jun-30-25 02:28PM	Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters (GlobeNewswire)
09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
Jun-18-25 08:30AM	Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery (GlobeNewswire)
Jun-10-25 09:15AM	Tevogen expands headquarters in Warren, New Jersey (TipRanks) +12.73%
Jun-09-25 09:00AM	Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives (GlobeNewswire) -23.08%
May-30-25 11:01AM	Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships (GlobeNewswire)
May-25-25 06:19PM	Tevogen Peports Plans to Increase the Target Population for TVGN 489 (Insider Monkey)
May-23-25 03:49PM	Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow (GlobeNewswire) +6.50%
May-22-25 01:21PM	Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting (GlobeNewswire)
May-12-25 08:00AM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +9.17%
May-05-25 12:35PM	AI Healthcare Boom Gains Speed as Regulators and Innovators Align (PR Newswire)
May-02-25 03:45PM	Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest (GlobeNewswire)
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.01%
Apr-30-25 03:49PM	CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment (GlobeNewswire)
Apr-29-25 04:50PM	Tevogen sees launch year oncology business revenue $1B (TipRanks) +7.74%
01:48PM	Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts (GlobeNewswire)
08:00AM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-28-25 04:36PM	Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion (GlobeNewswire) -5.52%
Apr-25-25 02:33PM	Tevogen Bio Announces 2025 Annual Meeting (GlobeNewswire)
Apr-17-25 02:54PM	Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility (GlobeNewswire)
Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Apr-15-25 02:03PM	Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction (GlobeNewswire)
Apr-14-25 01:53PM	Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald (GlobeNewswire)
Apr-11-25 04:00PM	Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints (Seeking Alpha) +8.00%
Apr-09-25 02:45PM	Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States (GlobeNewswire) +16.67%
Apr-08-25 05:53PM	Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs (GlobeNewswire) -6.80%
Apr-07-25 03:58PM	Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission (GlobeNewswire)
Mar-26-25 03:12PM	Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast (GlobeNewswire)
Mar-25-25 01:11PM	Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan (GlobeNewswire)
Mar-10-25 12:40PM	Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO (GlobeNewswire) -7.02%
Mar-07-25 04:09PM	Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel (GlobeNewswire)
Mar-03-25 12:52PM	Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations (GlobeNewswire) -7.81%
Feb-28-25 01:17PM	Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy (GlobeNewswire)
Feb-21-25 03:28PM	Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned (GlobeNewswire) -8.71%
Feb-14-25 06:31PM	Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision (GlobeNewswire)
01:16PM	Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency (GlobeNewswire)
11:52AM	Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation's Health and Prosperity (GlobeNewswire)
Feb-13-25 04:34PM	Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans (GlobeNewswire) -6.02%
Feb-10-25 05:30PM	Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation (GlobeNewswire) +5.44%
Feb-07-25 02:56PM	Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell Technology's Potential as a Scalable Medical Countermeasure (GlobeNewswire)
Jan-29-25 02:33PM	Tevogen Bio Holdings Inc. (TVGN): Accelerating Precision Medicine with Microsoft AI Collaboration (Insider Monkey) -5.23%
Jan-28-25 03:49PM	Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding (GlobeNewswire) -8.93%
Jan-27-25 02:24PM	Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach (GlobeNewswire) +24.44%
Jan-24-25 05:34PM	Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure (GlobeNewswire)
Jan-23-25 07:53PM	Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 12:21PM	Tevogen Bio to Host Panel Discussions AI In Biopharma: Next Frontier of Medical Innovation and Pioneering the Economics of Health: Balancing Access and Outcomes During J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-24 09:38AM	Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-24 08:30AM	Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda (GlobeNewswire) +12.14%
Dec-17-24 01:32PM	Tevogen Bio to Host Panel Pioneering the Economics of Health: Balancing Access and Outcomes During the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.88%
Dec-10-24 03:13PM	Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.77%
Dec-05-24 11:03AM	Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame (GlobeNewswire) -7.08%
Nov-26-24 08:05AM	Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy (GlobeNewswire) -5.63%
Nov-21-24 03:59PM	Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value (GlobeNewswire) +15.49%
Nov-19-24 04:50PM	Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model (GlobeNewswire)
Nov-14-24 05:00PM	UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials (GlobeNewswire) -17.78%
03:49PM	Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials (GlobeNewswire)
Nov-08-24 03:36PM	Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations (GlobeNewswire) +7.02%
Nov-05-24 04:43PM	Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability (GlobeNewswire) -12.24% -24.42%
09:27AM	Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 (GlobeNewswire)
Nov-04-24 02:36PM	Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support (GlobeNewswire) -17.30%
Oct-31-24 10:54AM	Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs (GlobeNewswire)
Oct-29-24 03:28PM	Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company (GlobeNewswire) -6.93%
02:38PM	Alpha Capital Appointed as Exclusive Financial Advisor to CD8 Technology to Secure Funding Up To $50 Million (GlobeNewswire)
12:43PM	Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity (GlobeNewswire)
Oct-25-24 05:34PM	Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas (GlobeNewswire) +19.14% -10.16%
Oct-23-24 08:35AM	Tevogen Bio's Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development (GlobeNewswire) +54.04%

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saadi Ryan H.	Chief Executive Officer	Jun 09 '25	Sale	1.23	1,438,206	1,768,993	116,814,453	Jun 09 07:13 PM
Saadi Ryan H.	Officer	Jun 09 '25	Proposed Sale	1.10	1,438,206	1,582,027		Jun 09 05:45 PM
Flomenberg Neal	See Remarks	Mar 12 '25	Sale	1.09	232,968	253,935	3,595,608	Mar 14 09:02 PM
Flomenberg Neal	See Remarks	Mar 07 '25	Sale	1.14	71,273	81,251	3,969,212	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 10 '25	Sale	1.09	70,384	76,719	3,898,828	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 11 '25	Sale	1.05	70,252	73,765	3,828,576	Mar 11 08:52 PM
Flomenberg Neal	See Remarks	Mar 05 '25	Sale	1.21	110,659	133,897	4,129,004	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Mar 06 '25	Sale	1.10	88,519	97,371	4,040,485	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Mar 04 '25	Sale	1.28	14,639	18,738	4,239,663	Mar 06 09:41 PM
Flomenberg Neal	See Remarks	Oct 17 '24	Sale	1.62	1,078,600	1,747,332	4,254,302	Oct 18 09:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVGN

Tevogen Bio Holdings Inc

Upgrade your FINVIZ experience